$CYTO News
Last published 1y ago
- 1y agoCYTOCYTOFAltamira Therapeutics Announces Transition from NASDAQ to OTC MarketsGlobeNewswireHAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol "CYTOF"No reverse stock split planned Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company
- 2y agoCYTOAltamira Therapeutics Provides Update on Nasdaq ListingGlobeNewswireHamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that it received on September 30, 2024, a letter from the Listing
- 2y agoCYTOAltamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SprayGlobeNewswireHamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding
- 2y agoCYTOAltamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCYTOAltamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsGlobeNewswireHamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new R&D facilities
- 2y agoCYTOAltamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024GlobeNewswireHamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery
- 2y agoCYTOAltamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingGlobeNewswireHamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira
- 2y agoCYTOAltamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingGlobeNewswireHamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants
- 2y agoCYTOAltamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East AsiaGlobeNewswireHamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization
- 2y agoCYTOAltamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11GlobeNewswireHamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery
- 2y agoCYTODiamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)GlobeNewswireNEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on Altamira Therapeutics Ltd.
- 2y agoCYTOAltamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkGlobeNewswireHamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark Altamira
- 2y agoCYTOAltamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesGlobeNewswireHamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of themOutcome further confirms Bentrio's suitability for use by
- 2y agoCYTOAltamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsGlobeNewswireHamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology results in significant reduction in tumor growth
- 2y agoCYTOAltamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesGlobeNewswireHamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysmAltamira's
- 2y agoCYTOAltamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementGlobeNewswireHamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Independent review discusses evidence supporting the use of betahistine to alleviate residual dizziness following physical repositioning procedures in
- 2y agoCYTOAltamira Therapeutics Provides Business UpdateGlobeNewswireHamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy asset in vertigo and /
- 2y agoABBVCYTOONCYPFE+1Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032GlobeNewswirePALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis,
- 2y agoCYTOAltamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalGlobeNewswireHamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA
- 2y agoCYTOAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationGlobeNewswireHamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA
- 2y agoCYTOAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalGlobeNewswireHamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint
- 2y agoCREVCYTOZAPPDiamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024GlobeNewswireNEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Investor Conference on April 18, 2024. The
- 2y agoCYTODiamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)GlobeNewswireNEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Altamira Therapeutics Ltd.
- 2y agoCYTOAltamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCYTOAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsGlobeNewswireHamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new applicationsPartnering
- 2y agoCYTOAltamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024GlobeNewswireHamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery
- 2y agoCYTOAltamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesGlobeNewswireHAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Univercells to test proprietary mRNA vaccine delivered with Altamira's SemaPhore™ nanoparticlesTargeting safer and accessible mRNA vaccines Altamira
- 2y agoCYTOAltamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalGlobeNewswireHAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating
- 2y agoCYTOAltamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentGlobeNewswireHAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira's polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines Fresh
- 2y agoCYTOAltamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitGlobeNewswireHAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira's two flagship programs, AM-401 and AM-411, designed for
- 2y agoCYTOAltamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireHAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based
- 2y agoCYTOAltamira Therapeutics Ltd. (CYTO) Special Call TranscriptEarnings Call Transcripts
- 2y agoCYTOAltamira Therapeutics Provides Investor and Business UpdateGlobeNewswireHAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business first step in transition to become ‘pure
- 2y agoCYTOAltamira Therapeutics to Host Investor & Business Update Call on December 11thGlobeNewswireHAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing
- 2y agoCYTOAltamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementGlobeNewswire- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29, 2023 (GLOBE
- 2y agoCYTOAltamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessGlobeNewswireInitiates Strategic Repositioning to Focus on Company's Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue Hamilton,
- 3y agoCYTOAltamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineGlobeNewswireHamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics
- 3y agoCYTOAltamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic RhinitisGlobeNewswireHAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in treatment of seasonal
- 3y agoCYTOAltamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsGlobeNewswireHAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical company initiated for
- 3y agoCYTOAltamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12thGlobeNewswireHAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet
- 3y agoCYTOAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13GlobeNewswireHAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet
- 3y agoCYTOAltamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaGlobeNewswireHAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet
- 3y agoCYTOAltamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalGlobeNewswireHAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy-Study demonstrates statistically significant alleviation of nasal
- 3y agoCYTOAltamira Therapeutics Announces Pricing of $5.0 Million Public OfferingACCESS NewswireHAMILTON, BERMUDA / ACCESSWIRE / July 6, 2023 / Altamira Therapeutics Ltd. , a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver,
- 3y agoCYTOAltamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac RegenerationGlobeNewswireHAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira's OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira Therapeutics Ltd. ("Altamira"
- 3y agoCYTOAltamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular SyndromeACCESS NewswireHAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. , a company dedicated to developing therapeutics that address important unmet
- 3y agoCYTOAltamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic TargetsACCESS NewswireHAMILTON, BERMUDA / ACCESSWIRE / May 31, 2023 / Altamira Therapeutics Ltd. , a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a
- 3y agoCYTOAltamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic RhinitisACCESS NewswireBentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitisClinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray
- 3y agoCYTOAltamira Therapeutics Provides Business Update, Reports FY 2022 Financial ResultsACCESS NewswireManagement will host an investor conference call today, May 16th, at 8 a.m. EasternCompany is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects
- 3y agoCYTOAltamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023ACCESS NewswireHAMILTON, BERMUDA / ACCESSWIRE / May 12, 2023 / Altamira Therapeutics Ltd. , a company dedicated to developing and commercializing RNA delivery technology for extrahepatic targets, announced that it will